
Biotech firm Intra-Cellular Therapies has appointed former NICE chairman Professor Sir Michael Rawlins to its Board of directors. Rawlins was …

NICE is to be responsible next year for assessing high cost drugs for people with rare medical conditions as part …

The National Institute for Health and Clinical Excellence (NICE) has reappointed Professor Sir Michael Rawlins as NICE chairman for a …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

